Benign uterine tumor
Conditions
Interventions
Uterine fibroids cohort -HIFU group:None
Uterine fibroids cohort – control group:None
Adenomyosis cohort – HIFU group:None
Adenomyosis cohort – control group:None
CSP (cesarean scar pregnancy) cohort – HIFU group:None
CSP (cesarean scar pregnancy) cohort – control group:None
Placenta accreta spectrum (PAS) cohort – HIFU group:None
Placenta accreta spectrum (PAS) cohort– control group:None
Sponsors
The Second Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Female, aged 18–55 years (for CSP/PAS, may be relaxed to 18–50 years). 2. Diagnosed by imaging (ultrasound/MRI) or clinical criteria as having any of the following benign uterine diseases: (1) Uterine fibroids (according to FIGO classification); (2) Adenomyosis (according to MRI/ultrasound JZ features and morphology); (3) CSP (meeting international CSP diagnostic criteria); (4) PAS (based on MRI or ultrasound blood flow grading and intraoperative findings). 3. Retrospective: received either HIFU or conventional treatment since 2022; Prospective: planned to receive HIFU and agree to follow-up. 4. Agree to follow-up (informed consent required for prospective part); informed consent waived for retrospective study.
Exclusion criteria
Exclusion criteria: 1. Malignant tumor or suspected malignancy; 2. Requiring emergency treatment and unable to complete evaluation; 3. Severe organ dysfunction precluding follow-up; 4. Missing critical data that cannot be supplemented; 5. Unable to understand or cooperate with follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| menstrual volume;bleeding volume during treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| pregnancy rate;live birth rate;residual myometrial thickness;residual placental volume; | — |
Countries
China
Contacts
Public Contactxiaojing dong
The Second Affiliated Hospital of Chongqing Medical University
Outcome results
None listed